home / stock / nnvc / nnvc news

NNVC News and Press, NanoViricides Inc.

Stock Information
Company Name: NanoViricides Inc.
Stock Symbol: NNVC
Market: NYSE
Website: nanoviricides.com
Menu
Get NNVC Alerts

News, Short Squeeze, Breakout and More Instantly...
NNVC - As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola

SHELTON, CT / ACCESS Newswire / July 22, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has applied to the regulatory agency, ACOREP, for approval to begin a Phase II Clinical...
NNVC - As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo

SHELTON, CT / ACCESS Newswire / July 13, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, announces that it has received National Ethics Committee approval for a Phase II Clinical Trial of NV-387 O...

NNVC - MissionIRNewsBreaks - NanoViricides (NYSE American: NNVC) Coverage Initiated With Outperform Rating, $6 Price Target

2026-07-08 09:25:00 ET NanoViricides, Inc. (NYSE American: NNVC) announced that independent analyst Robert LeBoyer of Noble Capital Markets has initiated research coverage of the clinical-stage antiviral drug developer with an “Outperform” rating and a $6.00 price target. ...

NNVC - Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily

SHELTON, CT / ACCESS Newswire / July 8, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, reports that a Coverage Initiating Research Report on the Company by an Independent Analyst has been publish...
NNVC - InvestorNewsBreaks - NanoViricides (NYSE American: NNVC) Advances NV-387 Toward Phase II Trial for Bundibugyo Ebola in DRC

2026-07-06 09:35:00 ET NanoViricides, Inc. (NYSE American: NNVC) announced continued progress advancing its broad-spectrum antiviral drug candidate NV-387 toward a Phase II clinical trial evaluating its oral gummies formulation as a treatment for the current Bundibugyo ebolavirus outbre...

NNVC - As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo

SHELTON, CT / ACCESS Newswire / July 6, 2026 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, updates that it has continued to advance its broad-spectrum antiviral drug NV-387 towards a Phase II Clinica...

NNVC - US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher

SHELTON, CT / ACCESS Newswire / June 29, 2026 / NanoViricides, Inc., a publicly traded company (NYSE American: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot ...
NNVC - BioMedNewsBreaks - NanoViricides (NYSE American: NNVC) Ships NV-387 Drug Supply to DRC for Phase II MPox Trial 

2026-06-22 10:28:29 ET NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company said site preparations are be...

NNVC - NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo

SHELTON, CT / ACCESS Newswire / June 22, 2026 / NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company") today announced that it has shipped the NV-387 Oral Gummies Drug Product for a Phase II Clinical Trial of Monkeypox Treatment to the Democratic Republic of Congo (DRC), in preparation for en...

NNVC - NetworkNewsBreaks - NanoViricides (NYSE American: NNVC) Receives DRC Approval to Advance Proposed Phase II Ebola Trial

2026-06-15 09:05:00 ET NanoViricides, Inc. (NYSE American: NNVC) announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved the company’s proposal to conduct a Phase II clinical trial evaluating NV-387 Oral Gummies as a treatment for the curren...
Next 10